Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
Sarah Parisi,1 Carlo Finelli2 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologi...
Main Authors: | Parisi S, Finelli C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-12-01
|
Series: | Journal of Blood Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/prognostic-factors-and-clinical-considerations-for-iron-chelation-ther-peer-reviewed-fulltext-article-JBM |
Similar Items
-
Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR
by: Felicitas Schulz, et al.
Published: (2023-10-01) -
The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies
by: Artur Słomka, et al.
Published: (2024-01-01) -
The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia
by: Sarah Weber, et al.
Published: (2021-02-01) -
A Review on Iron Chelators in Treatment of Iron Overload Syndromes
by: Naser Mobarra, et al.
Published: (2016-10-01) -
The effects of secondary iron overload and iron chelation on a radiation-induced acute myeloid leukemia mouse model
by: Lap Shu Alan Chan, et al.
Published: (2021-05-01)